New biomarkers defining a novel early stage of Fabry nephropathy: A diagnostic test study

Autor: Rui Pinto, Derralynn Hughes, José Luís Ducla Soares, Carlos Cardoso, Olga Azevedo, Patricio Aguiar, Robert Baker, Jacira Marino
Přispěvatelé: Universidade do Minho
Rok vydání: 2017
Předmět:
Male
0301 basic medicine
Pathology
beta-N-Acetyl-Galactosaminidase
Endocrinology
Diabetes and Metabolism
Medicina Básica [Ciências Médicas]
030232 urology & nephrology
Kidney
urologic and male genital diseases
Biochemistry
Diabetic nephropathy
0302 clinical medicine
Endocrinology
Prospective Studies
Enzyme replacement therapy
Middle Aged
3. Good health
Ciências Médicas::Medicina Básica
Disease Progression
Female
medicine.symptom
Adult
Collagen Type IV
medicine.medical_specialty
Urology
Renal function
Nephropathy
N-acetyl-beta-glucosaminidase
Young Adult
03 medical and health sciences
Genetics
medicine
Albuminuria
Humans
Renal Insufficiency
Chronic
Molecular Biology
Aged
N-acetyl-β-glucosaminidase
Science & Technology
urogenital system
business.industry
medicine.disease
Fabry disease
Cross-Sectional Studies
Early Diagnosis
030104 developmental biology
Fabry disease nephropathy
Fabry Disease
Alanine aminopeptidase
business
Biomarkers
Kidney disease
Zdroj: Repositório Científico de Acesso Aberto de Portugal
Repositório Científico de Acesso Aberto de Portugal (RCAAP)
instacron:RCAAP
ISSN: 1096-7192
DOI: 10.1016/j.ymgme.2017.05.007
Popis: Renal involvement in Fabry disease is a major determinant of overall disease prognosis and early enzyme replacement therapy seems effective in preventing progression of kidney injury. Gb3 storage, glomerular sclerosis and tubulo-interstitial fibrosis may occur with minimal or no changes on standard renal tests, hence alternative markers of renal dysfunction are crucial. In this study we compared several biomarkers with albuminuria in the identification of incipient Fabry nephropathy and their diagnostic accuracy to identify chronic kidney disease (CKD) stage≥2.
nvestigator-initiated research grant from Shire Pharmaceuticals (grant number: IIR-PRT-000784). The funder did not have role in: study design; collection, analysis and interpretation of data; writing the report; the decision to submit the report for publication
Databáze: OpenAIRE
Externí odkaz: